FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to immunology, cell biotechnologies, and can be used for recovery of anti-tumour immunity and tumour growth inhibition with further application in the clinical practice. Disclosed is a method for tumour growth inhibition in experiment, which comprises using macrophages with blocking anti-inflammatory transcription factors STAT3 and STAT6, wherein before blocking anti-inflammatory transcription factors STAT3 and STAT6, macrophages are being exposed with the serum-free medium, then with cytokine IFN-γ in the concentration of 20 ng/ml.
EFFECT: technical result is forming macrophages with M3 phenotype, or selection phenotype possessing the effective anti-tumour mechanisms, resistant to reprogramming tumour effects.
1 cl, 3 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TUMOUR GROWTH INHIBITION BASED ON IN VITRO REPROGRAMMING MACROPHAGES ON M1 PHENOTYPE WITH HIGH ABILITY OF NITRIC OXIDE PRODUCTION IN EXPERIMENT | 2015 |
|
RU2599545C1 |
| METHOD OF SUPPRESSION OF INFLAMMATORY RESPONSE IN PERIODONTAL TISSUES IN AN EXPERIMENT | 2017 |
|
RU2677642C1 |
| USE OF GRAPHENE OXIDE TO ACTIVATE PHAGOCYTIC FUNCTION OF MACROPHAGES | 2022 |
|
RU2809372C1 |
| METHOD FOR IDENTIFYING FUNCTIONAL M1 AND M2 PHENOTYPE OF HUMAN MACROPHAGES GENERATED IN VITRO FROM BLOOD MONOCYTES | 2019 |
|
RU2717024C1 |
| METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
| METHOD OF SUBCUTANEOUS TRANSPLANT GROWTH INHIBITION OF EXPERIMENTAL HUMAN GLIOBLASTOMA U-87, TRANSPLANTED TO IMMUNODEFICIENT MICE Nu/J | 2019 |
|
RU2717218C1 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| METHOD FOR OBTAINING PRIMARY MACROPHAGE LINES WITH PRO-INFLAMMATORY PROPERTIES | 2022 |
|
RU2792602C1 |
| METHOD OF ALTERING IMMUNOMODULATING PROPERTIES OF LIPOPOLYSACCHARIDES OF PLAGUE BACTERIA IN VITRO | 2011 |
|
RU2489755C1 |
| METHOD FOR TREATING CANCER BY TARGETING SUPPRESSOR CELLS OF MYELOID ORIGIN | 2017 |
|
RU2776899C2 |
